Related Experiment Videos
Long-term therapy for pulmonary hypertension in children
1St. Louis Children's Hospital, MO 63110, USA. dent@a1.kids.wustl.edu
Insights
Recent advances in pediatric pulmonary hypertension reveal links between vascular tone regulation and disease, offering hope for new treatments. Current therapies include inhaled nitric oxide, prostacyclin, and calcium channel blockers, with lung transplantation as a last resort.
Area of Science:
- Pediatric cardiology
- Pulmonary vascular disease
- Neonatal physiology
Background:
- Pulmonary hypertension in infancy and childhood presents significant mortality and morbidity.
- Understanding the underlying physiological mechanisms is crucial for effective treatment.
- Existing therapeutic strategies have limitations in progressive disease.
Purpose of the Study:
- To review recent advances in the understanding of pediatric pulmonary hypertension.
- To discuss current and emerging therapeutic interventions.
- To highlight the connection between physiological regulation and disease pathology.
Main Methods:
- Literature review of recent scientific discoveries.
- Analysis of physiological mechanisms in pulmonary vascular tone regulation.
- Synthesis of current treatment modalities and their efficacy.
Main Results:
- New insights into the physiological basis of pulmonary hypertension.
- Identification of links between normal vascular tone regulation and disease states.
- Evaluation of short-term (inhaled nitric oxide, prostacyclin) and long-term (calcium channel blockers) therapies.
Conclusions:
- Advances in understanding pulmonary hypertension offer hope for novel therapeutic targets.
- Current treatments focus on managing vasoconstriction.
- Lung transplantation remains a critical option for severe, progressive cases.
Abstract:
This review recounts recent advances in the understanding and treatment of the processes that cause pulmonary hypertension in infancy and childhood. New discoveries have begun to unveil connections between the basic physiological mechanisms responsible for the regulation of pulmonary vascular tone and the abnormal responses of the pulmonary vasculature in a variety of disease conditions. These discoveries raise hope for new therapeutic interventions that may improve the high mortality and morbidity of both children and adults with pulmonary vascular disease. In the meantime, treatment efforts continue to be focused on the relief of pulmonary vasoconstriction with inhaled nitric oxide and intravenous prostacyclin in the short term and oral calcium channel blockers as the mainstay of long-term therapy. Lung transplantation often remains as the only viable option for continued survival when the pulmonary vascular disease is progressive.